Xellia Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 20-06-2024
- Paid Up Capital ₹ 0.01 Cr
as on 20-06-2024
- Company Age 14 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 0.30%
(FY 2022)
- Profit 9.52%
(FY 2022)
- Ebitda 4.94%
(FY 2022)
- Net Worth 20.61%
(FY 2022)
- Total Assets 12.92%
(FY 2022)
About Xellia Pharmaceuticals
The Company is engaged in the Business Services Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 0.01 Cr, as per Ministry of Corporate Affairs (MCA) records.
Mikkel Olsen, Bente Nielsen, and Vidya Viswanathan serve as directors at the Company.
- CIN/LLPIN
U24230KA2010PTC055122
- Company No.
055122
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
13 Sep 2010
- Date of AGM
14 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangalore, Karnataka, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Xellia Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mikkel Olsen  | Director | 09-Mar-2011 | Current |
| Bente Nielsen | Director | 09-Mar-2011 | Current |
Vidya Viswanathan  | Director | 01-Feb-2020 | Current |
Financial Performance and Corporate Structure Insights of Xellia Pharmaceuticals.
Xellia Pharmaceuticals Private Limited, for the financial year ended 2022, experienced modest growth in revenue, with a 0.3% increase. The company also saw a slight improvement in profitability, with a 9.52% increase in profit. The company's net worth Soared by an impressive increase of 20.61%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Xellia Pharmaceuticals?
In 2020, Xellia Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Xellia Pharmaceuticals?
Xellia Pharmaceuticals has a workforce of 52 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Xellia Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Xellia Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
